Abu Dhabi, UAE — AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO® (tremelimumab) in the UAE.
The launch makes the UAE one of the first countries in the Middle East to receive access to the medication that marks a significant advancement in the treatment of cancer.
Clinical trials have demonstrated the efficacy and tolerability of IMJUDO® in combination in various types of cancer, including metastatic non-small cell lung cancer and hepatobiliary cancers. The drug has shown promising results in extending progression-free survival and overall survival rates, empowering patients with better treatment outcomes and a higher quality of life.
AstraZeneca hosted a series of workshops and sessions to introduce the new medications to healthcare experts in the UAE. The sessions saw the participation of over 100 healthcare professionals from major cancer healthcare facilities. During the sessions, several regional and international health care experts showcased the revolutionary data of using immunotherapy combination to improve the survival of liver and lung cancer patients who are in urgent need of new effective medications, noting the high unmet needs.
The UAE has over 30 cancer centres and clinics across the country.
Our mission is to continue to collaborate with our partners to transform health and wellbeing for people, society, and the planet,” Sameh El Fangary, GCC and Pakistan Cluster President at AstraZeneca, stated. “This collaboration highlights our unwavering commitment to accelerate the latest innovation to the UAE and to the region, inspired by our strategic focus to eliminate cancer-related deaths.”
Dr. Humaid Al Shamsi, Head of Emirates Oncology Society added: “IMJUDO® represents an important step in our global fight against several types of cancer, especially that the primary data supporting this revolutionary medication indicates that it is the first and only approved therapy in combination with IMFINZI® having 3-year data in first-line advanced or unresectable hepatocellular carcinoma.”
“This breakthrough immunotherapy drug offers new hope for patients and their families. We look forward to seeing the positive impact of IMJUDO® on patient outcomes and continuing our collaboration with AstraZeneca in the fight against cancer,” he added.